Comparative Pharmacology
Head-to-head clinical analysis: GENCEPT 10 11 21 versus GENCEPT 10 11 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENCEPT 10 11 21 versus GENCEPT 10 11 28.
GENCEPT 10/11-21 vs GENCEPT 10/11-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GENCEPT 10/11-21 is a combination contraceptive vaginal ring containing ethinyl estradiol and etonogestrel. Ethinyl estradiol is an estrogen that suppresses gonadotropin release, inhibiting ovulation. Etonogestrel is a progestin that thickens cervical mucus, inhibiting sperm penetration, and alters the endometrium.
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) inhibits ovulation by suppressing gonadotropin release, increases cervical mucus viscosity to impede sperm penetration, and alters endometrial receptivity.
One tablet (10 mg ethinyl estradiol and 11 mg gestodene on days 1-7, then placebo on days 8-21) orally once daily for 21 days, followed by 7 placebo days.
One tablet (ethinyl estradiol 0.01 mg/levonorgestrel 0.1 mg) orally once daily for 28 days. For the first 21 days, active tablets are taken; the next 7 days are placebo tablets.
None Documented
None Documented
Terminal elimination half-life is 24-30 hours; allows once-daily dosing; steady-state achieved in 5-7 days
Terminal elimination half-life is approximately 8-12 hours. Steady state is achieved within 2-3 days.
Renal (30-40% as unchanged drug and metabolites), biliary/fecal (50-60% as metabolites)
Renal excretion accounts for approximately 70% of elimination (as unchanged drug and metabolites), with about 10% biliary/fecal. The remaining is metabolized.
Category C
Category C
Oral Contraceptive
Oral Contraceptive